Apr 18 |
Buy Zymeworks Pioneering Cancer Treatments: Zanidatamab's Promising Data
|
Apr 11 |
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
|
Apr 8 |
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
|
Apr 1 |
Zymeworks shares sink after company removes CFO Christopher Astle
|
Mar 28 |
Zymeworks Announces Appointment of Dr. Neil Gallagher to its Board of Directors
|
Mar 7 |
Zymeworks files to sell 5.09M shares for holders
|
Mar 7 |
Zymeworks Inc. 2023 Q4 - Results - Earnings Call Presentation
|
Mar 7 |
Zymeworks Inc. (ZYME) Q4 2023 Earnings Call Transcript
|
Mar 6 |
Zymeworks files to sell 5.09M shares for its holders
|
Mar 6 |
Zymeworks Non-GAAP EPS of -$0.16 beats by $0.28, revenue of $16.92M misses by $0.74M
|